+

WO2004020599A3 - Antagonistes de la voie hedgehog, methodes et applications correspondantes - Google Patents

Antagonistes de la voie hedgehog, methodes et applications correspondantes Download PDF

Info

Publication number
WO2004020599A3
WO2004020599A3 PCT/US2003/027279 US0327279W WO2004020599A3 WO 2004020599 A3 WO2004020599 A3 WO 2004020599A3 US 0327279 W US0327279 W US 0327279W WO 2004020599 A3 WO2004020599 A3 WO 2004020599A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hedgehog antagonists
uses related
hedgehog pathway
inhibiting
Prior art date
Application number
PCT/US2003/027279
Other languages
English (en)
Other versions
WO2004020599A2 (fr
Inventor
Henryk K Dudek
Irina Karavanov
Carmen Pepicelli
Lee Rubin
Karen Kotkow
Original Assignee
Curis Inc
Henryk K Dudek
Irina Karavanov
Carmen Pepicelli
Lee Rubin
Karen Kotkow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Henryk K Dudek, Irina Karavanov, Carmen Pepicelli, Lee Rubin, Karen Kotkow filed Critical Curis Inc
Priority to AU2003265853A priority Critical patent/AU2003265853A1/en
Publication of WO2004020599A2 publication Critical patent/WO2004020599A2/fr
Publication of WO2004020599A3 publication Critical patent/WO2004020599A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des méthodes destinées à l'inhibition de l'angiogenèse et au traitement ou à la prévention de la prolifération cellulaire anormale, y compris des tumeurs, ces méthodes consistant à inhiber la voie hedgehog, à l'aide d'un des antagonistes de la voie hedgehog décrit dans la partie descriptive de la présente demande, par exemple.
PCT/US2003/027279 2002-08-29 2003-08-29 Antagonistes de la voie hedgehog, methodes et applications correspondantes WO2004020599A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265853A AU2003265853A1 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40714502P 2002-08-29 2002-08-29
US60/407,145 2002-08-29

Publications (2)

Publication Number Publication Date
WO2004020599A2 WO2004020599A2 (fr) 2004-03-11
WO2004020599A3 true WO2004020599A3 (fr) 2006-12-28

Family

ID=31978427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027279 WO2004020599A2 (fr) 2002-08-29 2003-08-29 Antagonistes de la voie hedgehog, methodes et applications correspondantes

Country Status (2)

Country Link
AU (1) AU2003265853A1 (fr)
WO (1) WO2004020599A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
CA2475879A1 (fr) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis de quinazolinones
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
WO2003097053A1 (fr) 2002-05-09 2003-11-27 Cytokinetics, Inc. Composes, compositions et procedes
EP1513820A4 (fr) 2002-05-23 2006-09-13 Cytokinetics Inc Composes, compositions et procedes
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
EP1692112A4 (fr) 2003-12-08 2008-09-24 Cytokinetics Inc Composes, compositions, et methodes associees
ES2707393T3 (es) * 2004-03-26 2019-04-03 Curis Inc Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos
US20090047282A1 (en) * 2005-03-25 2009-02-19 Hideaki Tojo Prophylactic/Therapeutic Agent for Cancer
NZ569293A (en) 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
ES2610130T3 (es) 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101569949B1 (ko) 2008-02-26 2015-11-18 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 유도체 및 이의 용도
WO2009126840A1 (fr) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer
JP5442717B2 (ja) 2008-04-29 2014-03-12 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
PT2364185E (pt) 2008-11-03 2013-07-24 Lilly Co Eli Ftalazina dissubstituída antagonista da via hedgehog
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2462115B1 (fr) 2009-08-05 2016-01-06 Infinity Pharmaceuticals, Inc. Transamination enzymatique d'analogues de cyclopamine
WO2011024873A1 (fr) 2009-08-26 2011-03-03 武田薬品工業株式会社 Dérivé d'hétérocycle condensé et son utilisation
EP2471789B9 (fr) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Dérivé à noyaux hétérocycliques fusionnés et son utilisation
WO2011024871A1 (fr) 2009-08-26 2011-03-03 武田薬品工業株式会社 Dérivé à noyaux hétérocycliques fusionnés et son utilisation
GEP20146075B (en) 2009-08-26 2014-04-10 Takeda Pharmaceuticals Co Fused heterocyclic ring derivative and usage thereof
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012037217A1 (fr) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Hydrogénation par transfert d'analogues de cyclopamine
CA2817577A1 (fr) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Composes heterocycliques et utilisations de ceux-ci
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RS58023B2 (sr) 2012-11-01 2021-12-31 Infinity Pharmaceuticals Inc Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
WO2014085523A1 (fr) 2012-11-29 2014-06-05 Strasspharma Llc Procédés de modulation de l'activité de l'hormone folliculo-stimulante
CA2904794C (fr) 2013-03-15 2021-11-23 Peter Walter Modulateurs de la voie eif2 alpha
WO2014151386A1 (fr) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN105682658B (zh) 2013-05-30 2022-04-05 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015061204A1 (fr) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CN104906113A (zh) * 2014-03-12 2015-09-16 淄博赛维医药技术有限公司 一种抗肿瘤药物
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (fr) 2016-02-11 2017-08-17 PellePharm, Inc. Inhibiteur de la voie hedgehog destiné à être utilisé pour soulager et traiter le prurit ou les démangeaisons
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
CN110709096B (zh) 2017-05-05 2023-10-31 泽兰德制药公司 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
EP4229828A4 (fr) 2020-10-13 2024-08-28 Endeavor Biomedicines, Inc. Méthodes de traitement de la fibrose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJITA E. ET AL.: "Involvement of Sonic Hedgehog in the Cell Growth of LK-2 cells, Human Lung Squamous Carcinoma Cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH, vol. 238, 1997, pages 658 - 664, XP003005586 *
MCGARVEY T.W. ET AL.: "PTCH gene mutations in invasive transitional cell carcinoma of the bladder", ONCOGENE, vol. 17, 1998, pages 1167 - 1172, XP003005585 *
TAIPALE J. ET AL.: "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine", NATURE, vol. 406, 31 August 2000 (2000-08-31), pages 1005 - 1009, XP002166408 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones

Also Published As

Publication number Publication date
AU2003265853A8 (en) 2004-03-19
AU2003265853A1 (en) 2004-03-19
WO2004020599A2 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004020599A3 (fr) Antagonistes de la voie hedgehog, methodes et applications correspondantes
WO2002030462A3 (fr) Antagonistes hedgehog, procedes et utilisations associees
WO2002032874A3 (fr) Composes heterocycliques substitues pour le traitement de resistance a des medicaments multiples
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
AU3741801A (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2005030129A3 (fr) Inhibiteurs des canaux potassiques a la quinoleine
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2002046171A3 (fr) Derives d'anilinopyrimidine utilises comme inhibiteurs de kinase i$g(k)b (ikk), compositions et techniques associees
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
WO2004022537A3 (fr) Composes heterocycliques
WO2001071022A3 (fr) Agonistes et antagonistes du recepteur lpa et procedes d'utilisation de ces derniers
WO2005110994A3 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
WO2008036410A3 (fr) Méthodes et compositions de traitement de la sclérose latérale amyotrophique (sla)
WO2005046578A3 (fr) Inhibiteurs du canal potassique isoquinolinone
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
WO2006128143A3 (fr) Composes a base d'hydantoine
WO2004014893A3 (fr) Quinolones anti-microbiens, leurs compositions et utilisation
WO2005030130A3 (fr) Inhibiteurs des canaux potassiques a l'isoquinoleine
WO2007016087A3 (fr) Antagonistes des récepteurs de cgrp de benzodiazépine hétérocyclique
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2006065820A3 (fr) Inhibiteurs de la proteine kinase erk et utilisations
WO2006034113A3 (fr) Analogues de quinolone
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载